This work was produced by Guthrie et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Guthrie B, Rogers G, Livingstone S, et al. The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis. Southampton (UK): National Institute for Health and Care Research; 2024 Feb. (Health and Social Care Delivery Research, No. 12.04.)
The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.
Show detailsSupplementary methods
Accounting for competing risk of non-cardiovascular death
As explained in the main text (see Accounting for competing risk of non-cardiovascular death, p.91), the critical covariate for our relative survival models is Δlogit(Q), that is the difference between an individual’s predicted 10-year QFracture-2012 score and the average score for a person of the same age and sex. We estimate the latter using a regression on the CPRD data set. Table 57 shows the model coefficients and Figure 61 shows the model fitted for men and women as a function of age.
Supplementary results
Threshold at which treatment becomes associated with positive net benefit according to the generalised additive model adjusting for age and fracture risk
The threshold at which treatment becomes associated with positive net benefit according to the GAM and adjusting for age and fracture risk is shown in Table 58.
Cost-effectiveness of bisphosphonates for the primary prevention of osteoporotic fragility fracture: meta-model accounting for age, sex and baseline fracture risk
The meta-model takes the form:
Figure 62 shows the fitted model for men and women at indicative ages of 50, 60, 70 and 80 years, and Table 59 tabulates the threshold at which net benefit becomes positive (assuming that decision-makers value QALYs at £20,000 each).
- Supplementary methods and results for model assessing cost-effectiveness of bisp...Supplementary methods and results for model assessing cost-effectiveness of bisphosphonates for the primary prevention of osteoporotic fragility fracture - The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis
Your browsing activity is empty.
Activity recording is turned off.
See more...